Stocks to Watch Tomorrow , July 14, 2026 —–>> Monday was another tough session for chip stocks, with SK Hynix’s Nasdaq ADR debut triggering fresh selling across the semiconductor complex — Micron fell nearly 6% in premarket, SanDisk, Western Digital, and AMD all declined, and SKHYV shares dropped sharply in Korean trading before US markets even opened. But Tuesday doesn’t belong to semiconductors. Tuesday belongs to inflation, banks, and Kevin Warsh.

At 8:30 AM ET, the Bureau of Labor Statistics releases June CPI — the single most consequential data point in weeks. Before the bell, five mega-banks report simultaneously. And at 10:00 AM, Chair Warsh takes the hot seat at the House Financial Services Committee for his first-ever congressional testimony. Beyond the headline names, three genuinely underappreciated setups deserve attention. Here are all 10.

📊 Today’s Market Close — The Context for Tomorrow

💥 THE MACRO EVENT: June CPI — Tuesday 8:30 AM ET

Before any stock picks: this is the binary event of the week.

• Prior headline CPI: 4.2% YoY (May 2026) — more than double the Fed’s 2% target
• Prior core CPI: 3.4% YoY
• The market consensus expects modest deceleration driven by WTI crude’s drop from $120/barrel (April) to ~$70 (early July)
• Oil’s 42% decline from peak could subtract 0.3–0.5 percentage points from the headline number
• Core CPI (ex-energy) is where the Fed’s focus is — if it stays above 3.3%, Warsh’s hawkish bias stays intact

Scenario reactions:

• CPI below 3.8%: Rally in growth and rate-sensitive stocks; September hike probability falls sharply
• CPI 3.8%–4.2%: Mixed; banks hold; tech cautious
• CPI above 4.2%: Risk-off hard; treasuries sell, yields spike; growth and small-cap names hit

🔩 1. Fastenal (NASDAQ: FAST) — The Industrial Economy’s Q2 Report Card

Reports: Tuesday, July 14 — Before Open | EPS Est: $0.33 | Revenue Est: +12.6% YoY

Fastenal is the industrial supply bellwether — B2B fasteners, safety products, and embedded inventory management for manufacturers and construction companies. Its Q2 results are one of the few industrial earnings prints that tell you something real about capital spending, factory activity, and supply chain normalization.

What to expect:

• Q1 2026 EPS: $0.30 (in line), Revenue: $2.20B (+12.4% YoY, in line)
• Q2 2026 EPS consensus: $0.33 (+13.8% YoY)
• Q2 2026 revenue expected to grow 12.6% YoY — improving from 8.6% growth in Q2 2025
• Zacks Earnings ESP: +1.32% — indicates analysts have quietly raised estimates; points toward an EPS beat
• Zacks Rank: #2 (Buy) — bullish signal
• Key watch: AI data center construction demand. Fastenal’s FMI (Fastenal Managed Inventory) devices are deployed in facilities where new server farms are being built. Demand strength here = direct read on AI infrastructure capex activity

Analyst targets: Jefferies Buy ($52), Baird Outperform ($50), DA Davidson/Barclays/JPMorgan Neutral (~$46). Conference call Tuesday at 9:00 AM ET — immediately after the release.

🏦 2. Citigroup (NYSE: C) — The Best-Performing Big Bank YTD Proves the Turnaround Is Real

Reports: Tuesday Before Open | YTD Performance: +18.9% | Sector Leader

Of the five banks reporting Tuesday morning, Citigroup carries the most narrative momentum. Under CEO Jane Fraser’s now three-year transformation plan, Citi has shed underperforming international retail divisions, streamlined its operating model, and refocused capital toward institutional clients, U.S. personal banking, and treasury services. The market has rewarded this — Citi is the best-performing of the Big Five banks in 2026 at +18.9% YTD.

What Tuesday will confirm or deny:

• Whether investment banking fee recovery (seen at Goldman Sachs and Morgan Stanley) is filtering into Citi’s institutional franchise
• Whether the international headcount reduction created meaningful efficiency gains
• Citi’s exposure to geopolitical risk through international operations (Iran, EM exposure) is an explicit risk factor for 2026

🏦 3. Wells Fargo (NYSE: WFC) — The Biggest Recovery Story Among the Big Banks

Reports: Tuesday Before Open | YTD: −7.2% (Worst of 5) | EPS Est: $1.72 (+7.5% YoY) | Revenue Est: $21.85B (+4.9% YoY)

Wells Fargo is simultaneously the most underperforming and most potentially mispriced of the five big banks reporting Tuesday. The -7.2% YTD lag against Citigroup’s +18.9%, Goldman’s +18.3%, and Bank of America’s +7.2% creates a valuation gap that the Q2 print could close — if the right numbers are delivered.

The one catalyst that matters: Deutsche Bank analyst Matt O’Connor specifically cited the Federal Reserve’s formal removal of Wells Fargo’s asset growth restriction cap — a punitive measure in place since 2018 following the fake accounts scandal — as the primary reason to own WFC into 2H 2026. This cap prevented Wells from growing its balance sheet beyond 2017 levels for eight years. Its removal opens billions in new lending, investment banking, and capital markets capacity that competitors have been running unencumbered for nearly a decade.

Key numbers to watch Tuesday:

• Net interest margin (NIM) guidance for H2 2026
• Loan growth trajectory now that the cap is gone
• Any commentary on credit quality given the slowing jobs data (57,000 June NFP)
• Mortgage origination volumes — the housing market is being watched by the Fed

🧬 4. Kyverna Therapeutics (NASDAQ: KYTX) — The -13% Selloff Was an Overreaction. Here’s the Setup.

Current Price: ~$8.60 | 52-Week Range: $1.78 – $13.67 | Market Cap: ~$520M | Beta: 1.88

On Friday, July 10, JPMorgan trimmed KYTX’s price target by just $1 — from $30 to $29 — while maintaining an Overweight rating. The stock fell 12.8% in response. That disconnect defines the opportunity heading into Tuesday.

The fundamental story is completely intact:

• KYTX is developing the potential first commercially approved autoimmune CAR-T therapy — in a $15B+ market currently dominated by chronic immunosuppressants that treat symptoms, not cause
• Rolling BLA submission for miv-cel (KYV-101) in Stiff Person Syndrome (SPS) is ongoing — completion targeted Q4 2026; commercial launch potential H1 2027
• KYSA-8 Phase 3 results: 46% median improvement in the timed 25-foot walk test; 100% of patients went off chronic immunotherapies — clinical outcomes not previously seen in SPS
• Cash: $236.4M — funded into 2028 with no near-term dilution risk
• Added to Russell 2000 and Russell 3000 index families recently — creates passive fund buying floor

The numbers at the JPMorgan price target:

• JPM PT: $29 (still Overweight) vs. current price ~$8.60 — that’s 237% implied upside from a firm that just trimmed by $1
• KYTX has been up 215% over the past year despite Friday’s pullback
• 50-day MA: ~$8.72 — the critical level to hold Tuesday for bulls

💊 5. Madrigal Pharmaceuticals (NASDAQ: MDGL) — The MASH Leader Running Hot on StockTwits Today

Today’s Move: +4.16% | StockTwits Trending #9 | Q1 2026 Revenue: $311.34M (+127% YoY)

MDGL is Monday’s biggest Stocktwits trending name in healthcare — and for good reason. Madrigal has the only FDA-approved MASH (metabolic-associated steatohepatitis) treatment on the market, and it’s executing a near-flawless commercial launch.

Why it’s in focus heading into Tuesday:

• Q1 2026 revenue: $311.34M — beat consensus of $300.92M by 3.5%; up 127% year-over-year
• 42,250+ patients now on Rezdiffra (resmetirom) globally — prescriber adoption running ahead of expectations
• European approval achieved — Rezdiffra is now approved in the EU with labeling that does not require a liver biopsy — a key commercial differentiator vs. how earlier NASH treatments were positioned
• Analyst targets: Truist raised to $709 (Buy); Evercore ISI: $649 (Outperform); analyst consensus: ~$671
• Current trading range: $540–$580 area heading into Tuesday; today’s +4.16% adding ~$22 to the price

Upcoming catalyst: Q2 2026 earnings (expected August 2026). Watch for Q2 Rezdiffra net revenue — analysts expect continued 100%+ YoY growth.

💾 6. SK Hynix ADR (OTC: SKHYV) — The Chip Giant That’s Dragging the Sector. Watch the Stabilization.

Raised: $26.5B in Nasdaq ADR IPO | Korean Shares: Down Sharply Monday | HBM Market Leader

SK Hynix’s Nasdaq listing raised $26.5 billion — one of the largest U.S. listings in years. But what followed was a textbook post-listing profit-taking event: Korean institutional investors who received allocations in the $26.5B ADR sale rushed to sell Korean shares when trading resumed, depressing the Korean-listed stock and sending sympathy waves through every semiconductor name globally.

Why Tuesday matters for SKHYV:

• Post-IPO volatility typically stabilizes within 1–3 sessions after the institutional selling is absorbed
• SK Hynix is the world’s second-largest memory chip maker and the leader in HBM (High Bandwidth Memory) — the most critical component in Nvidia’s H100 and Blackwell AI chips
• SK Hynix Q2 2026 earnings are forthcoming — another catalyst to watch
• If SKHYV stabilizes and recovers on Tuesday, it could signal the chip sector has found a floor — a massive read-through for MU, SNDK, NVDA, and AMD

🏦 7. FB Financial Corp (NYSE: FBK) — The Regional Bank Reporting Tuesday That Nobody’s Talking About

Reports: Tuesday | Sector: Community Banking | Opportunity: M&A Consolidation Wave

FB Financial Corporation is a Tennessee-based community bank with about $13 billion in assets — a name that doesn’t make financial headlines but does make a difference in how traders position around the broader regional bank M&A consolidation wave. Community bank M&A is running at its fastest pace in years, with acquirers targeting franchise-rich, deposit-sticky institutions in Southeastern growth markets.

FBK’s Tuesday report will be parsed for: NIM trajectory, deposit cost pressure normalization, and any management commentary on strategic alternatives. This is a potential M&A target, not just an earnings play.

💉 8. Merck (NYSE: MRK) — The Defensive Pharma Trending Ahead of CPI

Today’s Move: +1.22% | StockTwits Trending #1 | Sector: Pharmaceuticals

Merck is the leading name on today’s Stocktwits trending board — and the reason is almost certainly macro-defensive positioning ahead of Tuesday’s CPI print. When investors are uncertain about inflation and rate direction, dividend-paying pharmaceutical blue chips like Merck attract capital as a hedge.

Keytruda (pembrolizumab), Merck’s blockbuster cancer immunotherapy, continues to expand its indications — with additional FDA approvals expected in H2 2026 for earlier-stage lung and bladder cancer indications. MRK’s dividend yield (~2.5–3%) acts as an income floor that CPI volatility can’t easily strip away.

💰 9. BlackRock (NYSE: BLK) — Wednesday’s Earnings Need Tuesday’s Positioning

StockTwits Move Today: +1.61% | Reports: Wednesday, July 15

BlackRock reports Q2 2026 results Wednesday morning before the open — and the Stocktwits activity today at +1.61% is Tuesday-eve positioning. As the world’s largest asset manager with ~$11+ trillion in AUM, BlackRock’s quarterly results will reveal: net inflows vs. outflows, market appreciation impact on AUM (H1 2026 was +9.5% for the S&P 500), and how fee revenues tracked given the chip-led rally that dominated the first half.

Any commentary on institutional appetite for AI infrastructure ETFs, private credit products, or geopolitical risk overlays will be scrutinized by the market for what it implies about institutional positioning in H2 2026.

🔬 10. ASML (NASDAQ: ASML) — The Chip Equipment Giant Reporting Wednesday, Positioning Tuesday

StockTwits Move Today: +0.38% | Reports: Wednesday, July 16 | Sector: Semiconductor Equipment

ASML’s Tuesday presence on the StockTwits trending board is a positioning trade for Wednesday’s earnings. ASML makes the extreme ultraviolet (EUV) lithography machines that every advanced chipmaker on earth requires — TSMC, Samsung, Intel, and SK Hynix are all customers.

Why Wednesday’s ASML earnings matter for the entire chip space:

• ASML’s order book is the advance indicator of what chipmakers plan to spend on capacity expansion 12–24 months from now
• If ASML reports strong new orders, it validates the AI chip capex cycle even amid July’s selloff
• If orders disappoint, it suggests chip companies are pulling back on future capacity investment — a bearish signal that could deepen the current SOX selloff

ASML reports Wednesday before the European market opens — which means U.S. premarket trading Tuesday night/Wednesday morning is where the real positioning happens.

📅 Tuesday’s Full Calendar

Follow TNN for daily stock market news and financial news today.

Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. All market investments carry inherent risks of capital loss. Always complete independent due diligence prior to executing equity trades. CPI data and earnings releases can cause sudden, sharp market movements in either direction. Prices referenced reflect July 13, 2026 intraday conditions. Past performance is not indicative of future results.

Further Reading:

• Bureau of Labor Statistics CPI Release — July 14, 2026
• Fastenal Investor Relations — Q2 2026 Earnings
• Kyverna Therapeutics Investor Relations
• Madrigal Pharmaceuticals — Rezdiffra Commercial Update
• Federal Reserve — Warsh Congressional Testimony
• CME FedWatch Tool — Rate Hike Probability
• Wells Fargo Investor Relations
• ASML Investor Relations — Q2 2026 Earnings

About The Author

Kasia Davis

See author's posts